Oxford Immunotec Global (NASDAQ:OXFD) Downgraded by TheStreet

TheStreet downgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a c- rating to a d+ rating in a research note issued to investors on Monday morning, TheStreetRatingsTable reports.

OXFD has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. BidaskClub downgraded shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, June 26th. Finally, ValuEngine upgraded shares of Zynerba Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $18.00.

OXFD stock opened at $12.91 on Monday. Oxford Immunotec Global has a 12-month low of $11.66 and a 12-month high of $19.19. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. The stock has a market cap of $353.82 million, a P/E ratio of 25.31 and a beta of 0.35. The business has a 50 day moving average of $14.07.

Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The company had revenue of $14.79 million during the quarter, compared to the consensus estimate of $13.74 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The company’s revenue was up 26.6% compared to the same quarter last year. As a group, analysts expect that Oxford Immunotec Global will post -0.24 EPS for the current fiscal year.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $16.05, for a total transaction of $48,150.00. Following the transaction, the director now owns 3,000 shares in the company, valued at approximately $48,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.21% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its holdings in shares of Oxford Immunotec Global by 59,988.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock valued at $93,000 after purchasing an additional 5,399 shares in the last quarter. Squarepoint Ops LLC raised its holdings in shares of Oxford Immunotec Global by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock valued at $247,000 after purchasing an additional 5,120 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its holdings in shares of Oxford Immunotec Global by 15.0% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock valued at $343,000 after purchasing an additional 3,255 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Oxford Immunotec Global by 50.7% during the 4th quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock valued at $419,000 after purchasing an additional 11,022 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Oxford Immunotec Global by 972.3% during the 1st quarter. Acadian Asset Management LLC now owns 33,969 shares of the company’s stock valued at $586,000 after purchasing an additional 30,801 shares in the last quarter. Institutional investors and hedge funds own 91.18% of the company’s stock.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Featured Story: Why is the price-sales ratio important?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.